Journal article

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017

Selma Ugurel, Joachim Roehmel, Paolo A Ascierto, Keith T Flaherty, Jean Jacques Grob, Axel Hauschild, James Larkin, Georgina V Long, Paul Lorigan, Grant A McArthur, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Claus Garbe

European Journal of Cancer | ELSEVIER SCI LTD | Published : 2017

University of Melbourne Researchers

Grants

Funding Acknowledgements

Selma Ugurel received relevant financial support from Bristol-Myers Squibb, medac, Merck Sharp & Dohme, Roche. Paolo A. Ascierto received relevant financial support as the advisory board/consultant for Bristol-Myers Squibb, Roche, Merck Sharp & Dohme, Array, Amgen, Novartis, Merck Serono, Pierre-Fabre; research fund from Bristol-Myers Squibb, Roche, Array. Keith T. Flaherty received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Jean Jacques Grob received relevant financial support from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche. Axel Hauschild received relevant financial support (Amgen, Bristol-Myers Squibb, MerckSerono, Merck Sharp & Dohme, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche). James Larkin received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Georgina V. Long received relevant financial support from Amgen, Array, Bristol-Myers Squibb, Novartis, Merck, OncoSec, Pierre-Fabre, Roche. Paul Lorigan received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Grant A. McArthur received relevant financial support from Pfizer, Celgene. Antoni Ribas received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Caroline Robert received relevant financial support from Roche, GSK, Novartis, Amgen, BMS, Merck Sharp & Dohme. Dirk Schadendorf received relevant financial support from Roche, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Amgen, Boehringer Ingelheim, Leo. Claus Garbe received relevant financial support from Roche, GSK, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme. The remaining authors declare no conflict of interest.